MTOR and Alzheimer disease: Dihydrotanshinone I (DTSI) significantly inhibits mTOR phosphorylation via the AMPK/mTOR signaling pathway, thereby enhancing autophagy, increasing Aβ clearance, and reducing tau phosphorylation, which highlights the potential of DTSI in the treatment of AD (Bao et al., 2020).